Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial

DOI record: { "DOI": "10.3389/fmed.2022.844728", "ISSN": [ "2296-858X" ], "URL": "http://dx.doi.org/10.3389/fmed.2022.844728", "abstract": "<jats:sec><jats:title>Background</jats:title><jats:p>Nitazoxanide exerts antiviral activity <jats:italic>in vitro</jats:italic> and <jats:italic>in vivo</jats:italic> and anti-inflammatory effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms and a chest computed tomography scan suggestive of viral pneumonia or positive RT-PCR test for COVID-19 were enrolled. Patients were randomized 1:1 to receive nitazoxanide (500 mg) or placebo, 3 times daily, for 5 days, and were followed for 14 days. The primary outcome was intensive care unit admission due to the need for invasive mechanical ventilation. Secondary outcomes included clinical improvement, hospital discharge, oxygen requirements, death, and adverse events within 14 days.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of the 498 patients, 405 (202 in the nitazoxanide group and 203 in the placebo group) were included in the analyses. Admission to the intensive care unit did not differ between the groups (hazard ratio [95% confidence interval], 0.68 [0.38–1.20], <jats:italic>p</jats:italic> = 0.179); death rates also did not differ. Nitazoxanide improved the clinical outcome (2.75 [2.21–3.43], <jats:italic>p</jats:italic> &amp;lt; 0.0001), time to hospital discharge (1.37 [1.11–1.71], <jats:italic>p</jats:italic> = 0.005), and reduced oxygen requirements (0.77 [0.64–0.94], <jats:italic>p</jats:italic> = 0.011). C-reactive protein, D-dimer, and ferritin levels were lower in the nitazoxanide group than the placebo group on day 7. No serious adverse events were observed.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Nitazoxanide, compared with placebo, did not prevent admission to the intensive care unit for patients hospitalized with COVID-19 pneumonia.</jats:p></jats:sec><jats:sec><jats:title>Clinical Trial Registration</jats:title><jats:p>Brazilian Registry of Clinical Trials (REBEC) RBR88bs9x; <jats:ext-link>ClinicalTrials.gov</jats:ext-link>, NCT04561219.</jats:p></jats:sec>", "alternative-id": [ "10.3389/fmed.2022.844728" ], "author": [ { "affiliation": [], "family": "Rocco", "given": "Patricia R. M.", "sequence": "first" }, { "affiliation": [], "family": "Silva", "given": "Pedro L.", "sequence": "additional" }, { "affiliation": [], "family": "Cruz", "given": "Fernanda F.", "sequence": "additional" }, { "affiliation": [], "family": "Tierno", "given": "Paulo F. G. M. M.", "sequence": "additional" }, { "affiliation": [], "family": "Rabello", "given": "Eucir", "sequence": "additional" }, { "affiliation": [], "family": "Junior", "given": "Jéfiton Cordeiro", "sequence": "additional" }, { "affiliation": [], "family": "Haag", "given": "Firmino", "sequence": "additional" }, { "affiliation": [], "family": "de Ávila", "given": "Renata E.", "sequence": "additional" }, { "affiliation": [], "family": "da Silva", "given": "Joana D. G.", "sequence": "additional" }, { "affiliation": [], "family": "Mamede", "given": "Mariana M. S.", "sequence": "additional" }, { "affiliation": [], "family": "Buchele", "given": "Konrad S.", "sequence": "additional" }, { "affiliation": [], "family": "Barbosa", "given": "Luiz C. V.", "sequence": "additional" }, { "affiliation": [], "family": "Cabral", "given": "Anna C.", "sequence": "additional" }, { "affiliation": [], "family": "Junqueira", "given": "Antônio A. F.", "sequence": "additional" }, { "affiliation": [], "family": "Araújo-Filho", "given": "João A.", "sequence": "additional" }, { "affiliation": [], "family": "da Costa", "given": "Lucianna A. T. J.", "sequence": "additional" }, { "affiliation": [], "family": "Alvarenga", "given": "Pedro P. M.", "sequence": "additional" }, { "affiliation": [], "family": "Moura", "given": "Alexandre S.", "sequence": "additional" }, { "affiliation": [], "family": "Carajeleascow", "given": "Ricardo", "sequence": "additional" }, { "affiliation": [], "family": "de Oliveira", "given": "Mirella C.", "sequence": "additional" }, { "affiliation": [], "family": "Silva", "given": "Roberta G. F.", "sequence": "additional" }, { "affiliation": [], "family": "Soares", "given": "Cynthia R. P.", "sequence": "additional" }, { "affiliation": [], "family": "Fernandes", "given": "Ana Paula S. M.", "sequence": "additional" }, { "affiliation": [], "family": "Fonseca", "given": "Flavio Guimarães", "sequence": "additional" }, { "affiliation": [], "family": "Camargos", "given": "Vidyleison Neves", "sequence": "additional" }, { "affiliation": [], "family": "Reis", "given": "Julia de Souza", "sequence": "additional" }, { "affiliation": [], "family": "Franchini", "given": "Kleber G.", "sequence": "additional" }, { "affiliation": [], "family": "Luiz", "given": "Ronir R.", "sequence": "additional" }, { "affiliation": [], "family": "Morais", "given": "Sirlei", "sequence": "additional" }, { "affiliation": [], "family": "Sverdloff", "given": "Carlos", "sequence": "additional" }, { "affiliation": [], "family": "Martins", "given": "Camila Marinelli", "sequence": "additional" }, { "affiliation": [], "family": "Felix", "given": "Nathane S.", "sequence": "additional" }, { "affiliation": [], "family": "Mattos-Silva", "given": "Paula", "sequence": "additional" }, { "affiliation": [], "family": "Nogueira", "given": "Caroline M. B.", "sequence": "additional" }, { "affiliation": [], "family": "Caldeira", "given": "Dayene A. F.", "sequence": "additional" }, { "affiliation": [], "family": "Pelosi", "given": "Paolo", "sequence": "additional" }, { "affiliation": [], "family": "Lapa-e-Silva", "given": "José R.", "sequence": "additional" } ], "container-title": "Frontiers in Medicine", "container-title-short": "Front. Med.", "content-domain": { "crossmark-restriction": true, "domain": [ "frontiersin.org" ] }, "created": { "date-parts": [ [ 2022, 4, 13 ] ], "date-time": "2022-04-13T05:56:55Z", "timestamp": 1649829415000 }, "deposited": { "date-parts": [ [ 2022, 4, 13 ] ], "date-time": "2022-04-13T05:56:59Z", "timestamp": 1649829419000 }, "funder": [ { "DOI": "10.13039/501100004809", "doi-asserted-by": "publisher", "name": "Financiadora de Estudos e Projetos" }, { "DOI": "10.13039/501100003593", "doi-asserted-by": "publisher", "name": "Conselho Nacional de Desenvolvimento Científico e Tecnológico" } ], "indexed": { "date-parts": [ [ 2022, 4, 13 ] ], "date-time": "2022-04-13T06:12:50Z", "timestamp": 1649830370058 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2022, 4, 13 ] ] }, "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 4, 13 ] ], "date-time": "2022-04-13T00:00:00Z", "timestamp": 1649808000000 } } ], "link": [ { "URL": "https://www.frontiersin.org/articles/10.3389/fmed.2022.844728/full", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1965", "original-title": [], "prefix": "10.3389", "published": { "date-parts": [ [ 2022, 4, 13 ] ] }, "published-online": { "date-parts": [ [ 2022, 4, 13 ] ] }, "publisher": "Frontiers Media SA", "reference": [ { "DOI": "10.1080/17476348.2020.1778470", "article-title": "Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2", "author": "Robba", "doi-asserted-by": "publisher", "first-page": "865", "journal-title": "Exp Rev Respir Med.", "key": "B1", "volume": "14", "year": "2020" }, { "DOI": "10.1056/NEJMoa2002032", "article-title": "Clinical characteristics of Coronavirus Disease 2019 in China", "author": "Guan", "doi-asserted-by": "publisher", "first-page": "1708", "journal-title": "N Engl J Med.", "key": "B2", "volume": "382", "year": "2020" }, { "DOI": "10.1056/NEJMcp2009575", "article-title": "Severe Covid-19", "author": "Berlin", "doi-asserted-by": "publisher", "first-page": "2451", "journal-title": "N Engl J Med.", "key": "B3", "volume": "383", "year": "2020" }, { "DOI": "10.1056/NEJMoa200776", "article-title": "Remdesivir for the treatment of Covid-19 - preliminary report", "author": "Beigel", "doi-asserted-by": "publisher", "first-page": "1813", "journal-title": "N Engl J Med.", "key": "B4", "volume": "383", "year": "2020" }, { "DOI": "10.1038/s41422-020-0282-0", "article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", "author": "Wang", "doi-asserted-by": "publisher", "first-page": "269", "journal-title": "Cell Res.", "key": "B5", "volume": "30", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)31022-9", "article-title": "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial", "author": "Wang", "doi-asserted-by": "publisher", "first-page": "1569", "journal-title": "Lancet.", "key": "B6", "volume": "395", "year": "2020" }, { "DOI": "10.1183/13993003.03725-2020", "article-title": "Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial", "author": "Rocco", "doi-asserted-by": "publisher", "first-page": "2003725", "journal-title": "Eur Respir J.", "key": "B7", "volume": "58", "year": "2021" }, { "DOI": "10.1016/j.intimp.2012.03.002", "article-title": "Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice", "author": "Hong", "doi-asserted-by": "publisher", "first-page": "23", "journal-title": "Int Immunopharmacol.", "key": "B8", "volume": "13", "year": "2012" }, { "DOI": "10.1007/s10753-019-00994-3", "article-title": "Tizoxanide inhibits inflammation in LPS-activated RAW264.7 macrophages via the suppression of NF-kappaB and MAPK activation", "author": "Shou", "doi-asserted-by": "publisher", "journal-title": "Inflammation.", "key": "B9", "year": "2019" }, { "DOI": "10.1016/j.eclinm.2021.100981", "article-title": "Nitazoxanide superiority to placebo to treat moderate COVID-19 - a pilot prove of concept randomized double-blind clinical trial", "author": "Blum", "doi-asserted-by": "publisher", "first-page": "100981", "journal-title": "EClinicalMedicine.", "key": "B10", "volume": "37", "year": "2021" }, { "DOI": "10.1016/j.eclinm.2022.101310", "article-title": "A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19", "author": "Rossignol", "doi-asserted-by": "publisher", "first-page": "101310", "journal-title": "EClinicalMedicine.", "key": "B11", "volume": "45", "year": "2022" }, { "DOI": "10.1016/S1473-3099(14)70717-0", "article-title": "Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial", "author": "Haffizulla", "doi-asserted-by": "publisher", "journal-title": "Lancet Infect Dis.", "key": "B12", "year": "2014" }, { "DOI": "10.1136/bmj.c332", "article-title": "CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials", "author": "Schulz", "doi-asserted-by": "publisher", "first-page": "c332", "journal-title": "BMJ.", "key": "B13", "volume": "340", "year": "2010" }, { "DOI": "10.1016/j.jbi.2019.103208", "article-title": "The REDCap consortium: building an international community of software platform partners", "author": "Harris", "doi-asserted-by": "publisher", "first-page": "103208", "journal-title": "J Biomed Inform.", "key": "B14", "volume": "95", "year": "2019" }, { "DOI": "10.1056/NEJMoa2031994", "article-title": "Baricitinib plus Remdesivir for hospitalized adults with Covid-19", "author": "Kalil", "doi-asserted-by": "publisher", "first-page": "795", "journal-title": "N Engl J Med.", "key": "B15", "volume": "384", "year": "2021" }, { "key": "B16", "volume-title": "R: A Language and Environment for Statistical Computing", "year": "2021" }, { "DOI": "10.1056/NEJMoa2021436", "article-title": "Dexamethasone in Hospitalized Patients with Covid-19", "author": "Horby", "doi-asserted-by": "publisher", "first-page": "693", "journal-title": "N Engl J Med.", "key": "B17", "volume": "384", "year": "2021" }, { "DOI": "10.1001/jama.2021.18295", "article-title": "Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial", "author": "Munch", "doi-asserted-by": "publisher", "first-page": "1807", "journal-title": "JAMA.", "key": "B18", "volume": "326", "year": "2021" }, { "DOI": "10.1016/j.dsx.2021.05.019", "article-title": "Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India", "author": "Singh", "doi-asserted-by": "publisher", "first-page": "102146", "journal-title": "Diabetes Metab Syndr.", "key": "B19", "volume": "15", "year": "2021" }, { "DOI": "10.1016/S2213-2600(21)00265-4", "article-title": "Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?", "author": "Raut", "doi-asserted-by": "publisher", "first-page": "e77", "journal-title": "Lancet Respir Med.", "key": "B20", "volume": "9", "year": "2021" } ], "reference-count": 20, "references-count": 20, "relation": {}, "resource": { "primary": { "URL": "https://www.frontiersin.org/articles/10.3389/fmed.2022.844728/full" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Medicine" ], "subtitle": [], "title": "Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.3389/crossmark-policy", "volume": "9" }